Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology […]
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology’s 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT […]
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified […]
Distinguished Cancer and Stem Cell Biologist Ulrich Steidl, M.D., Ph.D., Appointed Chair of Cell Biology at Albert Einstein College of Medicine
BRONX, N.Y., Nov. 22, 2022 /PRNewswire/ — Ulrich Steidl, M.D., Ph.D., an internationally recognized leader in cancer and stem cell biology, has been named the chair of the department of cell biology at Albert Einstein College of Medicine. Dr. Steidl assumes his new position as Arthur Skoultchi, Ph.D., who has led the department with distinction for 24 years, steps down from […]
The future of ALL treatment: moving away from stem cell transplantation
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into future treatment approaches in acute lymphoblastic leukemia (ALL), highlighting the growing role of inotuzumab ozogamicin, blinatumomab, and CAR-T cells. Dr Short further explains the importance of moving away from stem cell transplantation and bringing novel agents and CAR-T therapy […]
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]
What makes a stem cell a stem cell and how does it go bad?
Dr. John Dick was awarded the Canada Gairdner International Award 2022 “For the discovery and characterization of leukemic stem cells, providing insights into the understanding, diagnosis and treatment of acute myeloid leukemia.” He presented his award-winning research at the 2022 Gairdner Science Week Laureate Lectures.
Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
NEW YORK, Nov. 9, 2022 /PRNewswire/ — The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called […]
Stem Cell Clinical Trials and New Therapies for Patients: Alpha Clinic Director’s Panel
CIRM-funded Alpha Stem Cell Clinics are a network California medical centers that specialize in delivering stem cell clinical trials to patients. Sandra Dillon shares how their work has impacted treatments for her rare cancer. Maria T. Millan, M.D., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Sheila Chari, Ph.D., Noah Federman, M.D., Catriona Jamieson, M.D., […]